Lilly pill trumps Humira in arthritis study

(Reuters) - Eli Lilly and Co's experimental pill for rheumatoid arthritis proved superior to Abbvie Inc's leading injectable Humira treatment in a large study, which analysts said could prod them to raise sales forecasts for the medicine.